Monograph of Nystatin

Introduction/Overview

Nystatin is a polyene macrolide antifungal agent derived from the bacterium Streptomyces noursei. Historically, it has represented a cornerstone therapy for superficial mycoses, particularly Candida species, owing to its broad spectrum of activity and favorable safety profile when administered topically. In contemporary clinical practice, nystatin remains a key therapeutic option in pediatric and immunocompromised populations, offering an alternative to systemic azoles in situations where systemic exposure is undesirable or contraindicated.

Clinical relevance is underscored by the high prevalence of oral and cutaneous candidiasis in immunocompromised patients, including those with HIV/AIDS, cancer chemotherapy, and steroid therapy. Nystatin’s unique pharmacodynamic properties allow it to eradicate fungal pathogens while minimizing systemic toxicity. Consequently, a comprehensive understanding of its pharmacology is essential for optimizing patient outcomes, particularly in settings where alternative antifungal agents may pose significant risk.

• Identify the chemical classification and molecular structure of nystatin.
• Explain the principal pharmacodynamic mechanisms responsible for antifungal activity.
• Summarize the pharmacokinetic profile and its implications for dosing strategies.
• Outline approved therapeutic indications and common off‑label uses.
• Recognize major adverse effects, drug interactions, and special population considerations.

Classification

Drug Class and Chemical Category

Nystatin belongs to the polyene macrolide class of antifungal agents. Polyenes are characterized by a large lactone ring bearing multiple conjugated double bonds, which confer their distinctive binding properties and photochemical lability. The macrolide designation refers to the macrocyclic lactone ring, a structural motif shared with other antifungals such as amphotericin B.

Within the polyene class, nystatin is distinguished by its relatively low systemic absorption when administered orally. Its molecular formula is C₆₀H₁₀₁O₂₆, and it contains 17 conjugated double bonds that play a critical role in its interaction with fungal cell membranes. The drug is available in several formulations, including oral suspension, lozenges, topical creams, and powders for oral use, each tailored to specific clinical indications.

Mechanism of Action

Pharmacodynamics

The antifungal effect of nystatin is primarily mediated by its ability to bind ergosterol, an essential component of fungal cell membranes. This interaction results in the formation of transmembrane pores, leading to leakage of intracellular ions and metabolites. The overall effect is a decrease in cell membrane integrity, ultimately causing cell lysis and death.

Binding affinity to ergosterol is higher than to cholesterol, which accounts for the selective toxicity toward fungal cells. The pore-forming mechanism is concentration-dependent; at sub‑inhibitory concentrations, nystatin may also disrupt membrane fluidity, further compromising fungal viability. Additionally, nystatin’s interaction with ergosterol can inhibit the synthesis of phospholipids, thereby impeding cellular proliferation.

Molecular and Cellular Mechanisms

At the molecular level, nystatin interacts with ergosterol via hydrophobic interactions between its conjugated double bonds and the sterol’s ring structure. This binding localizes nystatin to the fungal membrane, where it oligomerizes to form aqueous channels. The resultant ion flux, particularly of potassium, initiates a cascade of cellular events culminating in apoptosis-like pathways.

Beyond pore formation, nystatin may influence the activity of membrane-bound enzymes, such as cytochrome P450 isoforms involved in ergosterol synthesis. Though this secondary effect is less pronounced than the primary pore mechanism, it contributes to the cumulative antifungal activity.

Pharmacokinetics

Absorption

Oral administration of nystatin results in minimal systemic absorption. The drug’s large molecular size and hydrophilic character hinder passive diffusion across the gastrointestinal epithelium. Consequently, the majority of the administered dose remains within the lumen, exerting its effect locally on mucosal surfaces.

Topical formulations achieve higher local concentrations by direct application to the affected area. For oral suspension, the drug’s bioavailability is estimated to be <5 %, a figure that underscores its limited systemic exposure and associated low risk of systemic toxicity.

Distribution

Given the limited absorption, systemic distribution is negligible. Within the lumen, nystatin adheres to mucosal surfaces via electrostatic interactions and forms a depot that sustains antifungal activity. The drug’s partitioning into tissues is minimal; when systemic exposure occurs, distribution is largely confined to highly vascularized organs such as the liver and kidneys, albeit at low concentrations.

Metabolism

Metabolic transformation of nystatin is limited. The drug is largely excreted unchanged. Minor metabolic pathways may involve phase I oxidation by hepatic microsomal enzymes, but these reactions contribute insignificantly to the overall clearance.

Excretion

Renal excretion predominates, with the drug and its metabolites eliminated unchanged via glomerular filtration. In patients with impaired renal function, the half-life may extend modestly; however, the clinical significance remains limited due to the drug’s negligible systemic absorption.

Half‑Life and Dosing Considerations

The elimination half-life (t_1/2) of nystatin is approximately 8–12 hours in healthy adults when systemic exposure occurs. For topical or oral formulations, the resident half-life at the site of action is determined by local clearance mechanisms, including saliva flow and mucociliary clearance. Standard dosing regimens for oral suspension in infants and children typically involve 25 mg/kg/day divided into four doses, whereas adults receive 1 g/day divided into four doses. For topical preparations, a single application delivers a dose of 1–2 g, depending on the product.

Therapeutic Uses/Clinical Applications

Approved Indications

• Oral candidiasis (thrush) in infants and young children.
• Topical treatment of cutaneous candidiasis, including diaper dermatitis and interdigital fungal infections.
• Prevention of Candida colonization in patients undergoing chemotherapy or immunosuppressive therapy, when systemic antifungal therapy is contraindicated.

Off‑Label Uses

While not formally approved, nystatin is frequently employed in several off‑label contexts:

• Prophylaxis of oral candidiasis in adult patients receiving broad‑spectrum antibiotics.
• Treatment of superficial fungal infections caused by non‑Candida species, such as Trichophyton mentagrophytes.
• Adjunctive therapy for mucosal lesions associated with graft‑versus‑host disease.

Adverse Effects

Common Side Effects

Given the limited systemic absorption, adverse effects are predominantly localized. Reported local tolerability issues include:

• Gastrointestinal irritation, such as nausea and abdominal cramps.
• Oral mucosal irritation, characterized by burning or tingling sensations.
• Dermal irritation and rash at the application site.

Serious or Rare Adverse Reactions

Serious systemic reactions are exceedingly uncommon. Rare adverse events may comprise:

• Allergic dermatitis, manifesting as erythema, pruritus, or edema.
• Hemolytic anemia in patients with glucose‑6‑phosphate dehydrogenase deficiency, due to oxidative stress induced by the drug.
• Severe gastrointestinal disturbances, such as vomiting or diarrhea, in rare instances of high-dose systemic exposure.

Black Box Warnings

No black box warnings are currently assigned to nystatin. The safety profile is considered favorable, particularly in pediatric populations.

Drug Interactions

Major Drug‑Drug Interactions

Because nystatin is not extensively metabolized, interaction potential is limited. Nevertheless, concurrent use of medications that alter gastrointestinal pH or motility may affect local drug concentration:

• Proton pump inhibitors (PPIs) or H₂-receptor antagonists can reduce gastric acidity, potentially influencing the dissolution and local availability of orally administered nystatin.
• High‑dose corticosteroids may increase susceptibility to fungal infections, thereby necessitating vigilant monitoring when nystatin is used as prophylaxis.

Contraindications

Contraindications are restricted to hypersensitivity reactions. Patients with a documented allergy to nystatin or any component of the formulation should avoid all nystatin products. Cross‑reactivity with other polyene antifungals is possible, albeit infrequent.

Special Considerations

Pregnancy and Lactation

Safety data in pregnancy are limited but suggest minimal transplacental transfer due to the drug’s poor oral absorption. Consequently, nystatin is considered category B for pregnancy. For lactation, the drug is excreted in breast milk in negligible amounts; thus, it is generally regarded as safe for nursing mothers.

Pediatric Considerations

Pediatric dosing is weight‑based, with lower thresholds established for infants and young children to mitigate local irritation. Monitoring for signs of hypersensitivity is advised, especially in neonates who may exhibit increased mucosal permeability.

Geriatric Considerations

In elderly patients, decreased mucosal barrier function may enhance local irritation. Adjustments to dosing frequency are rarely required; however, vigilance for signs of systemic absorption is warranted in individuals with impaired renal function.

Renal and Hepatic Impairment

Because nystatin is primarily excreted unchanged via the kidneys, severe renal impairment may modestly prolong systemic half‑life. Nonetheless, given the low systemic exposure, dose adjustments are generally unnecessary. Hepatic impairment does not significantly alter pharmacokinetics, owing to minimal hepatic metabolism.

Summary/Key Points

• Nystatin is a polyene macrolide antifungal that exerts its effect by binding ergosterol and forming membrane pores, leading to fungal cell death.
• Limited systemic absorption confines local activity, resulting in a favorable safety profile with minimal systemic toxicity.
• Approved indications include oral and cutaneous candidiasis, with common off‑label uses in prophylaxis and treatment of superficial fungal infections.
• Adverse effects are predominantly local; serious systemic reactions are rare, and no black box warnings exist.
• Drug interactions are limited but may involve medications affecting gastric pH or immune status.
• Special populations—pregnant, lactating, pediatric, geriatric, and those with renal or hepatic impairment—require no routine dose modification but warrant monitoring for local tolerability.
• Overall, nystatin remains a valuable agent in the armamentarium against superficial fungal infections, particularly where systemic exposure is contraindicated or undesirable.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.